scholarly journals Real-world evidence of the impact of adalimumab on work productivity and sleep measures in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis

2020 ◽  
Vol 12 ◽  
pp. 1759720X2094908
Author(s):  
Maria G. Tektonidou ◽  
Gkikas Katsifis ◽  
Athanasios Georgountzos ◽  
Athina Theodoridou ◽  
Eftychia-Maria Koukli ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Psoriatic Arthritis ◽  
Ankylosing Spondylitis ◽  
Disease Activity ◽  
Real World ◽  
Sleep Problems ◽  
Work Productivity ◽  
Routine Care ◽  
Activity Impairment ◽  
Work Impairment

Objective: Our aim was to evaluate the effect of adalimumab on work productivity measures, overall activity impairment, and sleep quality in patients with active moderate to severe rheumatoid arthritis (RA), psoriatic arthritis (PsA), or ankylosing spondylitis (AS) treated in routine care settings in Greece and determine factors associated with work impairment and sleep disturbance. Methods: Patients with active moderate to severe RA ( n = 184), PsA ( n = 166), and AS ( n = 150) were enrolled in this 24-month, prospective, observational study at 80 hospital outpatient clinics and private practices throughout Greece. Patients received adalimumab alone or in combination with standard antirheumatic therapies according to routine care. Work productivity and sleep were assessed through two patient-reported outcome measures: the Work Productivity and Activity Impairment–General Health questionnaire and the Medical Outcomes Study Sleep Scale (MOS-SS). Pearson correlation coefficients were estimated to assess the association of work impairment and sleep disturbances with disease activity scores. Results: In the overall population, adalimumab significantly lowered absenteeism [mean (95% confidence interval) reduction, 18.9% (13.3–24.5%); n = 100]; presenteeism [40.0% (33.8–46.3%); n = 98], overall work productivity impairment [46.8% (40.4–53.2%); n = 94], activity impairment [47.0% (44.3–49.6); n = 421], and the MOS-SS sleep problems index [31.6 (29.5–34.1); n = 421] after 24-month treatment ( p < 0.001). Significant improvements were also noted across the RA, PsA, and AS subpopulations ( p < 0.05). Improvements in overall work impairment and sleep disturbance positively correlated with improvements in disease activity measures. Conclusion: Adalimumab improves work productivity and sleep problems while lowering disease activity in patients with moderate to severe RA, PsA, and AS managed in real-world settings.

scholarly journals Work Productivity is Associated With Disease Activity and Functional Ability in Chinese Patients With Axial Spondyloarthritis Using A Smart-Phone Management System: A Prospective Cohort Study

2020 ◽  
Author(s):  
Yanyan Wang ◽  
Xiaofei Liu ◽  
Wenji Chen ◽  
Shiyan Mo ◽  
Xiaojian Ji ◽  
...  
Keyword(s):  
Ankylosing Spondylitis ◽  
Disease Activity ◽  
Work Disability ◽  
Global Assessment ◽  
Clinical Characteristics ◽  
Axial Spondyloarthritis ◽  
Work Productivity ◽  
Smart Phone ◽  
Activity Impairment ◽  
Work Impairment

Abstract Background: Axial spondyloarthritis usually affects young people and often leads to disability. We used the interactive mobile health tool to evaluate clinical characteristics and loss of work efficiency in China, and to analyze the association between the clinical characteristics and work disability in patients with axial spondyloarthritis.Methods: In total, 1187 patients with axial spondyloarthritis were included. Demographic properties, pharmacotherapy, disease activity, functionality and spinal mobility were studied and compared in both work disability and non- work disability patients. Logistic regressions were used to investigate the associations between the risk of work disability and clinical characteristics. The relationships between Work Productivity and Activity Impairment scores and clinical characteristics were assessed using Spearman correlation coefficients. Results: Of the participants, 60 or 5.05% were unemployed. The predictive factors for the occurrence of work disability were suffering from inflammatory bowel disease, higher Physician’s global assessment and higher Assessment of Spondyloarthritis International Society health index (ASASHI) scores (OR value was 3.35, 1.32 and 1.45 respectively). Absenteeism, presenteeism, overall work impairment and activity impairment in all employed patients were 10.40%, 23.53%, 30.57% and 25.35% respectively. Factors significantly associated with higher presenteeism, overall work impairment and activity impairment loss were Bath Ankylosing Spondylitis Disease Activity Index, Bath Ankylosing Spondylitis Functional Index, Ankylosing Spondylitis Disease Activity Score, ASASHI, nocturnal pain, total back pain, and Patient’s global assessment (r >0.5), while non-steroidal anti-inflammatory drugs treatment were significantly associated with a lower absenteeism loss. An increased ASDAS score was related to a decrease in work productivity.Conclusions: We used a Smart-Phone Management System to determine that axial spondyloarthritis had a significant influence on working conditions in China, and that the factors related to the disease had a significant correlation with the risk and severity of lost work productivity. SpAMS is found be a time- and cost-saving disease management tool which can help patients with AS independently manage their disease and provide valuable data to their clinicians.

scholarly journals Real-World Postmarketing Study of the Impact of Adalimumab Treatment on Work Productivity and Activity Impairment in Patients with Psoriatic Arthritis

2019 ◽  
Vol 36 (3) ◽  
pp. 691-707
Author(s):  
Hidemi Nakagawa ◽  
Yoshiya Tanaka ◽  
Shigetoshi Sano ◽  
Hideto Kameda ◽  
Atsuo Taniguchi ◽  
...  
Keyword(s):  
Psoriatic Arthritis ◽  
Real World ◽  
Work Productivity ◽  
Activity Impairment ◽  
Adalimumab Treatment ◽  
The Impact

scholarly journals AB0927-PARE WORK PRODUCTIVITY AND ACTIVITY IMPAIRMENT IN PATIENTS WITH SAPHO SYNDROME

2021 ◽  
Vol 80 (Suppl 1) ◽  
pp. 1484.3-1485
Author(s):  
L. Gong ◽  
C. Li
Keyword(s):  
Rheumatoid Arthritis ◽  
Irritable Bowel Syndrome ◽  
Ankylosing Spondylitis ◽  
General Health ◽  
Productivity Loss ◽  
Work Productivity ◽  
Sapho Syndrome ◽  
Activity Impairment ◽  
Irritable Bowel ◽  
Disease Specific

Background:Synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome is a rare disease, characterized by osteoarticular and cutaneous manifestations. Osteitis and hyperostosis are regarded as the core pathophysiological changes of SAPHO syndrome [1], which may lead to bone pain and loss of motor function. The Work Productivity and Activity Impairment (WPAI) questionnaire is an instrument to measure the impact of the disease on work productivity and activity, subsequently adapted for ankylosing spondylitis [2], rheumatoid arthritis [3], irritable bowel syndrome [4], and other chronic diseases [5]. However, no study has investigated the work productivity of patients with SAPHO syndrome.Objectives:The purpose of this study is to give an overview of work productivity loss in SAPHO patients through the work productivity and activity impairment (WPAI) questionnaire and investigate the relationship between the WPAI and other disease-related indicators.Methods:Patients for this cross-sectional study were recruited from Peking Union Medical College Hospital (Beijing, China). The questionnaires incorporating the WPAI were administered, along with demographic data, disease-specific measures, and general health variables. The construct validity of WPAI was evaluated by the correlations between WPAI outcomes and other measures. Wilcoxon rank-sum tests and non-parametric Kruskal-Wallis tests were used for comparison of WPAI outcomes between known-groups.Results:A total of 376 patients were included and 201 patients (53.5%) were employed. The median (interquartile range [IQR]) of absenteeism, presenteeism, work productivity loss and activity impairment were 0% (0-13%), 20% (0-40%), 20% (0-52%) and 30% (0-50%), respectively. All WPAI outcomes showed moderate to strong correlations to other generic and disease-specific measures (|r| =0.43-0.75), except for absenteeism. Increasing disease activity and worse health status are significantly associated with higher impairment of work productivity and activity.Conclusion:This study highlights the negative effects of SAPHO syndrome on patients’ work productivity and activity, indicating a good construct validity and discriminative ability of WPAI. For reducing the economic burden, it is important to improve the patients’ work productivity and daily activity with active intervention.References:[1]Liu S, Tang M, Cao Y, Li C. Synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome: review and update. Therapeutic advances in musculoskeletal disease. 2020;12:1759720x20912865.[2]Reilly MC, Gooch KL, Wong RL, Kupper H, van der Heijde D. Validity, reliability and responsiveness of the Work Productivity and Activity Impairment Questionnaire in ankylosing spondylitis. Rheumatology (Oxford, England). 2010;49(4):812-819.[3]Zhang W, Bansback N, Boonen A, Young A, Singh A, Anis AH. Validity of the work productivity and activity impairment questionnaire--general health version in patients with rheumatoid arthritis. Arthritis research & therapy. 2010;12(5):R177.[4]Frandemark A, Tornblom H, Jakobsson S, Simren M. Work Productivity and Activity Impairment in Irritable Bowel Syndrome (IBS): A Multifaceted Problem. The American journal of gastroenterology. 2018;113(10):1540-1549.[5]Enns MW, Bernstein CN, Kroeker K, Graff L, Walker JR, Lix LM, et al. The association of fatigue, pain, depression and anxiety with work and activity impairment in immune mediated inflammatory diseases. PloS one. 2018;13(6):e0198975.Disclosure of Interests:None declared

scholarly journals Patient- and physician-reported outcomes from two phase 3 randomized studies (RAJ3 and RAJ4) of peficitinib (ASP015K) in Asian patients with rheumatoid arthritis

2021 ◽  
Vol 23 (1) ◽  
Author(s):  
Yoshiya Tanaka ◽  
Tsutomu Takeuchi ◽  
Hiroyuki Izutsu ◽  
Yuichiro Kaneko ◽  
Daisuke Kato ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Disease Activity ◽  
Daily Activity ◽  
Global Assessment ◽  
Work Productivity ◽  
Phase 3 ◽  
Activity Impairment ◽  
Link Type ◽  
Asian Patients ◽  
Domain Scores

Abstract Background Peficitinib (ASP015K), a novel oral Janus kinase inhibitor, has demonstrated efficacy and safety in the treatment of patients with rheumatoid arthritis (RA). This study evaluated the effect of peficitinib on patient- and physician-reported outcomes in Asian patients with RA and an inadequate response to prior disease-modifying antirheumatic drugs (DMARDs). Methods Patients from two randomized, placebo-controlled, double-blind, phase 3 trials (RAJ3 and RAJ4) received once-daily peficitinib 100 mg, peficitinib 150 mg, or placebo, alone or in combination with DMARDs (RAJ3), or in combination with methotrexate (RAJ4). Mean changes in Work Productivity and Activity Impairment (WPAI) questionnaire domain scores from baseline, and percentages of patients achieving minimal clinically important differences (MCIDs) for patient- and physician-reported outcomes (WPAI, Health Assessment Questionnaire – Disability Index [HAQ-DI], and Subject’s Global Assessment of Pain [SGAP]), and Physician’s Global Assessment of disease activity (PGA) were evaluated at weeks 4, 8, 12, and 12/early termination (ET). Results Data from 1025 patients were analyzed. At week 12/ET in both studies, patients who received peficitinib 100 mg or 150 mg reported significantly improved WPAI domain scores from baseline (except for absenteeism in RAJ4) compared with placebo (both doses, p<0.05). A higher proportion of peficitinib- versus placebo-treated patients achieved MCID in WPAI, HAQ-DI, SGAP, and PGA in studies RAJ3 and RAJ4. Significant differences with peficitinib versus placebo were evident in both studies as early as week 4 in HAQ-DI (peficitinib 150 mg only), SGAP, and PGA, and week 8 in WPAI loss of work productivity and daily activity impairment. At week 12/ET, significantly higher proportions of patients receiving peficitinib versus placebo achieved MCID in HAQ-DI, SGAP, PGA, and WPAI domains of presenteeism (RAJ3 only), loss of work productivity (RAJ3 only), and daily activity impairment (p<0.05 for all comparisons). Conclusions Peficitinib 100 mg or 150 mg administered daily over 12 weeks resulted in clinically meaningful improvements in outcomes that are important to RA patients, including pain, physical function, and work productivity and activity. These observations were reinforced through similar improvements in physicians’ rating of disease activity. Trial registration RAJ3: ClinicalTrials.gov, NCT02308163, registered 4 December 2014. RAJ4: ClinicalTrials.gov, NCT02305849, registered 3 December 2014.

scholarly journals Association of Nail Psoriasis With Disease Activity Measures and Impact in Psoriatic Arthritis: Data From the Corrona Psoriatic Arthritis/Spondyloarthritis Registry

2020 ◽  
pp. jrheum.190923
Author(s):  
Philip J. Mease ◽  
Mei Liu ◽  
Sabrina Rebello ◽  
Robert R. McLean ◽  
Blessing Dube ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Psoriatic Arthritis ◽  
Disease Activity ◽  
Work Productivity ◽  
Categorical Variables ◽  
Continuous Variables ◽  
Activity Impairment ◽  
Nail Psoriasis ◽  
Activity Measures

Objective To examine the association of nail psoriasis with disease activity, quality of life, and work productivity in patients with psoriatic arthritis (PsA). Methods All patients with PsA who enrolled in the Corrona PsA/Spondyloarthritis Registry between March 2013 and October 2018 and had data on physician-reported nail psoriasis were included and stratified by presence vs absence of nail psoriasis at enrollment. Patient demographics, disease activity, quality of life, and work productivity at enrollment were compared between patients with vs without nail psoriasis using t-tests or Wilcoxon rank-sum tests for continuous variables and χ2 or Fisher exact tests for categorical variables. Results Of the 2841 patients with PsA included, 1152 (40.5%) had nail psoriasis and 1689 (59.5%) did not. Higher proportions of patients with nail psoriasis were male (51.9% vs 44.1%) and disabled from working (12.3% vs 7.8%) compared with patients without nail psoriasis (all P < 0.05). Patients with nail psoriasis had higher disease activity than those without nail psoriasis, including higher tender and swollen joint counts, worse Disease Activity in Psoriatic Arthritis and Psoriatic Arthritis Disease Activity Score values, and increased likelihood of having enthesitis and dactylitis (all P< 0.05). Patients with nail psoriasis had worse pain, fatigue, and work and activity impairment than those without nail psoriasis (all P < 0.05). Conclusion Patients with PsA who have nail psoriasis had worse disease activity, quality of life, and work productivity than those without nail involvement, emphasizing the importance of identification and management of nail disease in patients with PsA.

Importance of Obtaining Remission for Work Productivity and Activity of Patients with Rheumatoid Arthritis

2017 ◽  
Vol 44 (8) ◽  
pp. 1112-1117 ◽  
Author(s):  
Dam Kim ◽  
Yuko Kaneko ◽  
Tsutomu Takeuchi
Keyword(s):  
Rheumatoid Arthritis ◽  
Linear Regression ◽  
Disease Activity ◽  
Work Performance ◽  
Work Productivity ◽  
Regression Analyses ◽  
Clinical Factors ◽  
Activity Impairment ◽  
Low Disease Activity

Objective.To identify the factors relevant to work and activity impairment in patients with rheumatoid arthritis.Methods.In total, 1274 consecutive patients were included. Work and activity impairment were measured by the Work Productivity and Activity Impairment questionnaire, and related clinical factors were examined.Results.Work and activity impairment was reported by 67.4% of the patients. Multivariable linear regression analyses revealed pain and non-remission to be associated with activity impairment and presenteeism. Patients in remission had significantly less activity impairment and presenteeism than those with low disease activity.Conclusion.Remission achievement is essential for ensuring work performance and activity.

Sign in / Sign up

Export Citation Format

Share Document